Innate Pharma S.A. Enterprise Value to EBITDA (EV/EBITDA) on July 03, 2025: -2.17

Innate Pharma S.A. Enterprise Value to EBITDA (EV/EBITDA) is -2.17 on July 03, 2025, a -85.83% change year over year. EV/EBITDA ratio compares the enterprise value to the EBITDA; lower suggests more favorable company valuation.
  • Innate Pharma S.A. 52-week low Enterprise Value to EBITDA (EV/EBITDA) is -2.09 on July 03, 2025, which is 3.75% above the current Enterprise Value to EBITDA (EV/EBITDA).
  • Innate Pharma S.A. 52-week low Enterprise Value to EBITDA (EV/EBITDA) is -17.17 on July 03, 2025, which is -690.44% below the current Enterprise Value to EBITDA (EV/EBITDA).
  • Innate Pharma S.A. average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is -10.53.
Key Data
Date Enterprise Value to EBITDA (EV/EBITDA) Free Cash Flow Yield Dividend Yield Market Capitalization